MOCTANIN
LOE Approachingmonoctanoin
NDAPERFUSION, BILIARYLIQUIDPriority Review
Approved
Oct 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOCTANIN (monoctanoin) is a biliary perfusion liquid approved in 1985 for dissolution of retained cholesterol gallstones in the biliary tract. It works as a solvent that directly contacts and dissolves stone material when infused through a catheter into the bile duct. This niche specialty product addresses a specific post-surgical complication with limited modern clinical use.
LOE Approaching
Product approaching loss of exclusivity with minimal modern market presence and likely small commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MOCTANIN has zero linked job openings and offers limited career growth opportunity as a legacy niche product in managed decline. Roles on this team would focus on maximizing remaining exclusivity, cost management, and eventual transition planning rather than market expansion.
Product ManagerCommercial Operations
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.